Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk that that the results of future clinical studies will not correlate or be consistent with the results of the completed studies to date and the risk that the company will experience delays or difficulties in enrolling patients in any planned future clinical studies. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are current
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... This report analyzes the worldwide markets for Bioinformatics ... and Biocontent. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:9/16/2014)... D.C., September 16, 2014 --The emerging field of ... to the next level, enabling the construction of ... efficient devices, individual molecules would take on the ... transistors. , A team of researchers from five ... candidate for use in small-scale electronics: a molecule ...
(Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
(Date:9/16/2014)... September 16, 2014 CIRTEC Medical Systems’ ... Highley as CEO of CIRTEC. , “I am ... for the Company.” noted Brian Highley. “The company has ... sustaining strong organic growth over the past two years. ... continuing to improve and expand the services Cirtec offers ...
Breaking Biology Technology:Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2
... 10% to $5.8 Billion, and Reported Diluted Earnings per Share Increased 19% to $0.75. ... ... $0.78, - 2007 Full Year Worldwide Net Revenue Increased 10% to $22.4 Billion and ... Before Certain Significant Items, Increased 12% to ...
... Inc., a,biotechnology company focused on the development of ... Petree and George R. Painter,Ph.D. to the Company,s ... founder and member of P2 Partners, LLC, a ... to forming P2,Partners, Mr. Petree held various executive ...
... A/S,(OMX: GEN) announces its financial calendar for 2008 as follows:, EVENT ... ... Annual General Meeting 2008 ... Wednesday, May 28, 2008 first quarter 2008, Publication of the Interim Report for ...
Cached Biology Technology:Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 2Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 3Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 4Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 5Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 6Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 7Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 8Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 9Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 10Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 11Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 12Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 13Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 14Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 15Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors 2Genmab's Financial Calendar for 2008 2
(Date:9/16/2014)... choices such as buying clothing not made in a ... bringing their own bags when they go shopping? According ... Consumer Research , ethical consumption is motivated by a ... practices into action. , "Advocates of ethical consumerism suggest ... of the products they choose, but unfortunately only a ...
(Date:9/16/2014)... , Sept. 16, 2014 As open enrollment ... important decisions about their 2015 benefits. According to ... solutions business of Aon plc (NYSE: ... a more proactive role in managing their health care ... ever for individuals to understand how they can make ...
(Date:9/15/2014)... a simple, mechanical solution to avoid chromosome sorting ... Science Express. , This natural ... lead to infertility, miscarriage, or congenital conditions. ... problems, but what exactly goes wrong is often ... Trust Center for Cell Biology at the University ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3
... Ore. The impact of hatcheries on salmon is so ... allow fish to survive and prosper in the hatchery environment, ... in a wild environment. These findings, published this week ... show a speed of evolution and natural selection that surprised ...
... NY The Cary Institute of Ecosystem Studies ... the National Science Foundation (NSF) to develop an ... on the Global Lake Ecological Observatory Network (GLEON), ... scientists, technology experts, engineers, and citizens using environmental ...
... and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have ... compounds with antimalarial activity and will provide it to researchers ... Box have confirmed activity against the blood-stage of P. ... and were selected by experienced medicinal chemists from an ...
Cached Biology News:Evolution at warp speed: Hatcheries change salmon genetics after a single generation 2Evolution at warp speed: Hatcheries change salmon genetics after a single generation 3National Science Foundation awards major grant to Cary Institute 2MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost 2
... Bioscience has over 23 years of experience ... We have made antibodies to large and ... viral antigens, and plasmid DNA-encoded antigens. We ... unique, so our hybridoma development programs are ...
... We deliversoluble protein or No Charge to ... best soluble protein results , 24 solubility ... , Powerful results on your most insoluble ... Service (SOS) uses proprietary tools and know-how ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
... With the macro- and micronutrients ... Skoog (1962) and the vitamins ... al. (1968). Preparation Quantity Equivalency: ... of powder per liter of ...
Biology Products: